Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E9.13 EPS (ttm)30.21 Insider Own0.63% Shs Outstand156.90M Perf Week9.23%
Market Cap42.09B Forward P/E10.99 EPS next Y25.10 Insider Trans0.17% Shs Float152.92M Perf Month10.90%
Income5.08B PEG- EPS next Q4.90 Inst Own88.00% Short Float2.51% Perf Quarter-4.56%
Sales14.26B P/S2.95 EPS this Y44.80% Inst Trans0.05% Short Ratio2.18 Perf Half Y-1.32%
Book/sh68.57 P/B4.02 EPS next Y-24.82% ROA19.60% Target Price290.48 Perf Year-5.89%
Cash/sh23.46 P/C11.76 EPS next 5Y-5.52% ROE42.40% 52W Range223.25 - 374.99 Perf YTD12.65%
Dividend- P/FCF6.61 EPS past 5Y20.50% ROI30.50% 52W High-26.44% Beta0.49
Dividend %- Quick Ratio1.80 Sales past 5Y8.20% Gross Margin87.60% 52W Low23.56% ATR6.93
Employees7400 Current Ratio2.10 Sales Q/Q-6.20% Oper. Margin46.70% RSI (14)69.39 Volatility3.97% 2.56%
OptionableYes Debt/Eq0.69 EPS Q/Q-46.80% Profit Margin35.60% Rel Volume0.98 Prev Close280.29
ShortableYes LT Debt/Eq0.69 EarningsOct 21 BMO Payout0.00% Avg Volume1.76M Price275.84
Recom2.70 SMA209.41% SMA509.78% SMA200-0.92% Volume1,733,079 Change-1.59%
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Nov-09-20Reiterated H.C. Wainwright Buy $318 → $289
Nov-09-20Downgrade Cowen Outperform → Market Perform $215
Nov-09-20Downgrade BofA Securities Neutral → Underperform $240
Nov-09-20Downgrade Atlantic Equities Neutral → Underweight $175
Nov-04-20Upgrade Wells Fargo Equal Weight → Overweight $390
Nov-04-20Upgrade Jefferies Hold → Buy $450
Nov-04-20Upgrade BofA Securities Underperform → Neutral
Oct-28-20Initiated UBS Neutral $268
Jul-27-20Upgrade Morgan Stanley Underweight → Overweight $263 → $357
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Jan-15-21 10:39AM  
Jan-14-21 03:29PM  
09:00AM  
Jan-13-21 09:35AM  
Jan-12-21 03:10PM  
12:10PM  
11:00AM  
10:25AM  
10:15AM  
09:50AM  
09:14AM  
08:56AM  
Jan-11-21 04:29PM  
02:01PM  
12:59PM  
12:33PM  
12:25PM  
11:42AM  
11:00AM  
11:00AM  
10:38AM  
09:28AM  
08:55AM  
08:00AM  
07:30AM  
Jan-10-21 10:25AM  
Jan-09-21 02:02PM  
Jan-08-21 09:00PM  
12:45PM  
12:00PM  
11:20AM  
11:00AM  
11:00AM  
09:07AM  
07:30AM  
Jan-07-21 01:40PM  
12:45PM  
11:25AM  
10:07AM  
06:20AM  
Jan-06-21 10:40PM  
09:30PM  
09:00PM  
11:30AM  
11:00AM  
11:00AM  
09:55AM  
09:11AM  
12:55AM  
Jan-05-21 09:10PM  
07:37PM  
12:40PM  
11:30AM  
11:30AM  
11:00AM  
09:47AM  
06:20AM  
02:00AM  
Jan-04-21 11:41PM  
02:15PM  
01:29PM  
11:30AM  
11:00AM  
11:00AM  
10:27AM  
06:36AM  
Jan-03-21 03:58AM  
Dec-30-20 06:20AM  
Dec-29-20 11:00PM  
05:25PM  
05:00PM  
01:30PM  
01:00PM  
11:45AM  
11:08AM  
Dec-28-20 01:00PM  
12:30PM  
11:35AM  
11:00AM  
10:20AM  
Dec-26-20 04:27PM  
Dec-24-20 07:34AM  
Dec-23-20 06:20AM  
12:40AM  
Dec-22-20 07:31PM  
06:00PM  
03:21PM  
01:50PM  
01:05PM  
01:02PM  
01:00PM  
12:00PM  
11:45AM  
11:45AM  
11:00AM  
Dec-21-20 07:30AM  
06:20AM  
Dec-20-20 12:54AM  
Dec-19-20 07:46AM  
Dec-18-20 04:25PM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM